Evidence map›Paper›PMID 34088300›Full record

ArticleBMC cancer2021

Comparison of therapeutic effects of chemo-radiotherapy with neoadjuvant chemotherapy before radical surgery in patients with bulky cervical carcinoma (stage IB3 & IIA2).

Setareh Akhavan, Abbas Alibakhshi, Mahdieh Parsapoor, Abbas Alipour, Elahe Rezayof

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Setareh AkhavanGynecology Oncology Ward, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Imam Khomeini Hospital Complex, Tohid Square, Tehran, 1419733141, Iran. s-akhavan@tums.ac.ir.
Abbas AlibakhshiGeneral Surgery Ward, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mahdieh ParsapoorGynecology Oncology Ward, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Imam Khomeini Hospital Complex, Tohid Square, Tehran, 1419733141, Iran.
Abbas AlipourCommunity Medicine Department, Medical Faculty, Thalassemia Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Elahe RezayofVali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRImam Khomeini Hospital · IRMazandaran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCervical cancer is one of the most common malignancies among women. Appropriate and timely treatment of these patients can reduce the complications and increase their survival. The objective of this study was to compare neoadjuvant chemotherapy plus radical hysterectomy (NACTRH) and chemo-radiotherapy (CRT) in patients with bulky cervical cancer (stage IB3 & IIA2). MATERIAL AND

methodsThe medical records of patients with bulky cervical cancer (stage IB3 & IIA2) that received NACTRH or CRT between 2007 and 2017 were evaluated for therapeutic effects. Demographic characteristics, complications of chemo-radiotherapy and neoadjuvant chemotherapy, were collected in a researcher-made questionnaire. Our primary outcome was comparison of overall survival (OS), and disease-free survival (DFS) between two groups receiving NACTRH and CRT modalities.

resultsOne-hundred and twenty three patients were enrolled in the study. The median age and the proportion of patients with stage IIA2 were higher in the CRT group compared to the NACTRH group (p < 0.05). The medians (95% CI) OS were 3.64 (3.95-6.45) and 3.9 (3.53-4.27) years in the NACTRH and CRT groups, respectively (P = 0.003). There were 16 (34.8%) and 22 (43.1%) recurrences in the NACTRH and CRT group, respectively (P = 0.4). The median (95% CI) DFS was 4.5 (3.88-5.12) years in the NACTRH group and 3.6 (2.85-4.35) years in the CRT group (P = 0.004). The 3-year OS rate in NACTRH and CRT groups were 97 and 90% respectively. The 3-year DFS rate in NACTRH and CRT groups were 88 and 66% respectively.

conclusionsNACTRH is associated with a higher OS and DFS compared to CRT.

Indexed as

HysterectomyAdultCarcinomaCervix UteriChemoradiotherapy, AdjuvantChemotherapy, AdjuvantDisease-Free SurvivalFemaleFollow-Up StudiesHumansMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingRetrospective StudiesTumor BurdenBulky massChemo-radiotherapyChemotherapyRadical hysterectomyUterine cervical neoplasms

Identifiers

PMID34088300
PMCPMC8178912
OpenAlexW3165461539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.